A California federal judge has tossed Takeda Pharmaceutical Co. Ltd.'s claim seeking declaratory judgment that Mylan Inc.'s planned generic version of the acid reflux drug Dexilant will infringe its patents, saying it "serves no purpose" since Takeda also alleges infringement under the Hatch-Waxman Act.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Direct access to case information and documents.
All significant new filings across U.S. federal district courts, updated hourly on business days.
Full-text searches on all patent complaints in federal courts.